August 2024 : Positive Phase 3 trial results for oral semaglutide were announced, enhancing patient adherence and convenience, strengthening Eli Lillys position in type 2 diabetes and obesity management markets
And underneath it all, cost continues to be the elephant in the room
Summary of the Major Provisions OPPS Update: For CY 2026, we are increasing the payment rates under the OPPS by an outpatient department (OPD) fee schedule increase factor of 2.6 percent
Log the date, dose, and injection site in your tracking method of choice
Castilla A, Giordano SR, Irazoqui G (2022) Extremophilic lipases and esterases: characteristics and industrial applications
The federal Centers for Disease Control and Prevention estimates that 34% of North Carolina adults compared with 40% nationally are obese